RAPT Therapeutics, Inc. RAPT
Set alert
58.01 USD 0.00 0.00%
As of Mar 6, 9:30 AM ET
58.01 Day range 58.01
26.50 52-week range 58.02
- YTD
- +71.26%
- 1 year
- +547.38%
- Open
- 58.01
- Prev close
- 58.01
- Mkt cap
- 1.61B
- Vol
- 10.85M
- Avg vol
- 4.25M
- EPS
- -11.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 58.01
- High
- 58.01
- Beta
- 0.44
- Inst. own
- 110.57%
- Dividend
- 0.00
Analyst view
Price target (mean) —
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 9
- 2 months ago 9
- 3 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.03 | -1.30 – -0.83 | -9.76 | +89.5% | 0 | 0.0% | 3 |
| Next quarter | -0.575 | -0.72 – -0.43 | -0.64 | +10.2% | 0 | 0.0% | 2 |
| Current year | -2.83 | -2.95 – -2.74 | -25.52 | +88.9% | 0 | 0.0% | 3 |
| Next year | -2.71 | -3.26 – -1.77 | -2.83 | +4.1% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 21, 2026 | Barclays | Downgrade | Overweight | Equal-Weight |
| Jan 21, 2026 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Jan 20, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Jan 20, 2026 | LifeSci Capital | Downgrade | Outperform | Market Perform |
| Jan 20, 2026 | TD Cowen | Downgrade | Buy | Hold |
| Jan 20, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 20, 2026 | Clear Street | Downgrade | Buy | Hold |
| Dec 18, 2025 | TD Cowen | Initiated | — | Buy |
| Nov 12, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 7, 2025 | Barclays | Maintained | Overweight | Overweight |
| Nov 3, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 27, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 27, 2025 | Guggenheim | Initiated | — | Buy |
| Oct 21, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 21, 2025 | Barclays | Maintained | Overweight | Overweight |
| Oct 21, 2025 | Clear Street | Maintained | Buy | Buy |
| Oct 20, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Oct 13, 2025 | Barclays | Initiated | — | Overweight |
| Sep 30, 2025 | Clear Street | Maintained | Buy | Buy |
| Sep 26, 2025 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Aug 12, 2025 | UBS | Maintained | Neutral | Neutral |
| Aug 8, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 30, 2025 | JP Morgan | Upgrade | Underweight | Neutral |
| Jul 22, 2025 | LifeSci Capital | Initiated | — | Outperform |
| Jul 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 22, 2025 | UBS | Maintained | Neutral | Neutral |
| Mar 10, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 26, 2024 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Nov 12, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
